Picture of Poseida Therapeutics logo

PSTX — Poseida Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMid CapMomentum Trap

Poseida Therapeutics Inc expected to post a loss of 76  cents a share - Earnings Preview

* Poseida Therapeutics Inc  PSTX.OQ   PSTX.O  is expected
to show
a rise in quarterly revenue when it reports  results on August
10 (estimated). 
    * The San Diego California-based  company is expected to
report
revenue of $1.059 million, according to the mean estimate from 4
analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for Poseida
Therapeutics Inc
is for a loss of 76 cents per share. For the same quarter last
year, the company reported a loss of 74 cents per share.
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Poseida
Therapeutics Inc is $16​, above​ its last closing price
of $4.11. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -0.65       -0.66      -0.93     Missed  -39.8
 Dec. 31 2022  -0.44       -0.35      0.02      Beat    105.8
 Sep. 30 2021  -0.74       -0.74      -0.68     Beat    8.5​
 Jun. 30 2021  -0.63       -0.63      -0.74     Missed  -17.5
 ​​Mar.        -0.64       -0.63      -0.62     Beat    2.4
 31 2021                                                
 Dec. 31 2020  -0.69       -0.69      -0.58     Beat    15.5​
 Sep. 30 2020  -0.55       -0.55      -0.63     Missed  -14.5
 Jun. 30 2020  -1.48       -1.48      -2.28     Missed  -54.1
 This summary was machine generated August 8 at 11:02 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on Poseida Therapeutics

See all news